Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOISES NEVAH RUBIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1841482429
CMS profile
871203
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$15,174.43

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $11,973.28 21
Novo Nordisk Inc $2,712.50 1
ABBVIE INC. $176.59 4
Cook Medical LLC $148.26 1
Salix Pharmaceuticals, a division of Bausch Health US, LLC $133.12 4
Ardelyx, Inc. $16.97 1
Intra-Sana Laboratories $13.71 1

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOISES NEVAH RUBIN

NPI 1841482429 · CMS profile ID 871203

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841482429?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOISES NEVAH RUBIN, NPI 1841482429, CMS profile ID 871203. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841482429?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MOISES NEVAH RUBIN, NPI 1841482429, CMS profile ID 871203. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841482429?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MOISES NEVAH RUBIN, NPI 1841482429, CMS profile ID 871203, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841482429?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $15,174.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $87.3911/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057108851 CMS
Novo Nordisk Inc $2,712.5011/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003160167 CMS
Gilead Sciences, Inc. $120.1311/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025514855 CMS
ABBVIE INC. $100.6509/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998000725 CMS
Cook Medical LLC $148.2608/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022742135 CMS
ABBVIE INC. $33.4508/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998000723 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.6208/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057497703 CMS
Gilead Sciences, Inc. $27.9807/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025581921 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.8606/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057354081 CMS
Gilead Sciences, Inc. $64.2005/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491953 CMS
Gilead Sciences, Inc. $28.2705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025578731 CMS
Gilead Sciences, Inc. $5,100.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035831583 CMS
ABBVIE INC. $27.7505/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998000721 CMS
Gilead Sciences, Inc. $239.1505/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491943 CMS
Gilead Sciences, Inc. $354.3305/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491947 CMS
Gilead Sciences, Inc. $1,338.9505/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491949 CMS
Gilead Sciences, Inc. $121.8405/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025512677 CMS
Gilead Sciences, Inc. $31.1303/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025557651 CMS
ABBVIE INC. $14.7403/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998000719 CMS
Gilead Sciences, Inc. $24.5002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491929 CMS
Gilead Sciences, Inc. $60.0002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491931 CMS
Gilead Sciences, Inc. $336.6802/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491935 CMS
Gilead Sciences, Inc. $431.8302/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491937 CMS
Gilead Sciences, Inc. $452.8102/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491941 CMS
Gilead Sciences, Inc. $124.7702/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025509497 CMS
Gilead Sciences, Inc. $49.9802/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025532771 CMS
Gilead Sciences, Inc. $49.9802/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025532775 CMS
Gilead Sciences, Inc. $12.7202/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026051509 CMS
Gilead Sciences, Inc. $4.0302/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026142081 CMS
Gilead Sciences, Inc. $3,000.0002/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035831579 CMS
Ardelyx, Inc. $16.9701/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052956551 CMS
Intra-Sana Laboratories $13.7101/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057050185 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2501/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057306261 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59,635.30 87
PY2020 $15,178.57 18
PY2021 $18,907.58 30
PY2022 $19,882.90 38
PY2023 $15,174.43 33
PY2024 $4,786.47 7
PY2025 $49,547.39 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $19,500.00 4
PY2023 Principal investigator $29,505.42 7
PY2022 Principal investigator $70,414.20 13
PY2021 Principal investigator $126,077.21 46
PY2020 Principal investigator $152,434.56 76
PY2019 Principal investigator $182,372.66 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $224.83 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HSC HOUSTON
A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection No dispute reported 06/30/2026 848751611
Principal investigator 1 Intercept Pharmaceuticals, Inc. $350.00 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836202639
Principal investigator 1 Intercept Pharmaceuticals, Inc. $950.00 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836202645
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,338.76 12/16/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836201991
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,717.00 12/15/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836201701
Principal investigator 1 Intercept Pharmaceuticals, Inc. $450.00 11/18/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836201057
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,600.00 11/18/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836201063
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,705.00 11/17/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836200673
Principal investigator 1 Intercept Pharmaceuticals, Inc. $128.00 10/28/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836200119
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,793.96 10/21/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836199803
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,432.85 10/20/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836199303
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,186.92 09/23/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836198189
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,105.00 09/02/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836197911
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,500.00 08/05/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836197567
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,886.70 08/04/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836197529
Principal investigator 1 Allergan, Inc. $1,100.00 07/23/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021351
Principal investigator 1 Allergan, Inc. $230.00 07/23/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021353
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,236.92 07/22/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836197369
Principal investigator 1 Intercept Pharmaceuticals, Inc. $600.00 07/14/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836197139
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,218.46 06/24/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196975
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,095.05 06/23/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196841
Principal investigator 1 Intercept Pharmaceuticals, Inc. $20,791.54 06/17/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196741
Principal investigator 1 Allergan, Inc. $770.00 06/15/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021349
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,275.00 06/09/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196659
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,761.50 06/02/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196595
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,020.50 06/02/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196597
Principal investigator 1 Intercept Pharmaceuticals, Inc. $968.50 06/02/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196599
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,625.00 06/02/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196601
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,395.35 05/26/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196469
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,401.54 05/20/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196357
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,368.80 05/06/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196087
Principal investigator 1 Intercept Pharmaceuticals, Inc. $325.00 04/21/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836195859
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,442.50 04/14/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836195707
Principal investigator 1 Allergan, Inc. $991.00 04/09/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021347
Principal investigator 1 Intercept Pharmaceuticals, Inc. $500.00 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836195585
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,579.50 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836195587
Principal investigator 1 Intercept Pharmaceuticals, Inc. $150.00 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) No dispute reported 06/30/2026 836195589
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,055.00 03/25/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836195507
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,094.83 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836195373
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,211.00 02/24/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194941
Principal investigator 1 Allergan, Inc. $2,090.00 02/19/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021345
Principal investigator 1 Intercept Pharmaceuticals, Inc. $682.00 02/11/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836194633
Principal investigator 1 Intercept Pharmaceuticals, Inc. $325.00 02/11/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836194635
Principal investigator 1 Intercept Pharmaceuticals, Inc. $487.50 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194389
Principal investigator 1 Intercept Pharmaceuticals, Inc. $9,826.70 01/26/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194307
Principal investigator 1 Allergan, Inc. $2,090.00 01/25/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789021343